Nephrology Transcenta's IND cleared for TST-004 for IgA nephropathy Oct. 6, 2022 No Comments Transcenta Holding Ltd. has received IND clearance from the FDA for TST-004, its best-in-class, humanized monoclonal antibody targeting mannose-binding protein-associated serine protease 2 (MASP2), for IgA nephropathy (IgAN).Read More